National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 7 of 1998)

Overview

The National Health Act 1953 was enacted to provide a legislative framework for the administration of national health services in Australia, including the Pharmaceutical Benefits Scheme (PBS). This Act was introduced to address the need for a structured and comprehensive approach to the provision and regulation of health services and pharmaceuticals in the country. The Act is administered by the Parliament of Australia, with the overarching policy objective of ensuring the availability and affordability of essential medicines to the public. A specific declaration under this Act, No. PB 7 of 1998, was issued to remove certain drugs and medicinal preparations from the scope of Part VII of the National Health Act 1953. This declaration, made by David Trevor Graham, Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Family Services, and acting on behalf of the Minister for Health and Family Services, was based on advice from the Pharmaceutical Benefits Advisory Committee. The declaration came into effect on 1 May 1998 and specified particular drugs and medicinal preparations that were to cease being subject to the provisions of the PBS.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations listed in the Schedule, which in this instance includes Aluminium Hydroxide, Dried with Magnesium Hydroxide and Oxethazaine, Chloramphenicol Sodium Succinate, and Methacycline Hydrochloride. This legislative instrument affects these particular substances by removing their eligibility for benefits under Part VII of the National Health Act 1953, a change that comes into effect on 1 May 1998. The Act is a Commonwealth legislation, extending its reach across the entire nation, and its application pertains directly to the pharmaceutical industry and healthcare providers involved in the supply and prescription of these medications. The Declaration is made by the Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Family Services, acting as the Minister’s delegate, following the advice of the Pharmaceutical Benefits Advisory Committee. It is worth noting that this legislative instrument does not explicitly mention any exclusions, exemptions, or thresholds, and its application is not extended or restricted through subordinate instruments.

Key Provisions

The key provisions of this legislative instrument, titled "Declaration under Subsection 85(2AA) of the National Health Act 1953," involve the removal of specific drugs and medicinal preparations from the scope of Part VII of the Act, which pertains to the Pharmaceutical Benefits Scheme (PBS). According to subsection 85(2AA), the Assistant Secretary of the Pharmaceutical Benefits Branch, after consulting the Pharmaceutical Benefits Advisory Committee, can make a declaration that certain drugs will no longer be covered by the PBS. This declaration is effective from 1 May 1998, as stated in section 2 of the instrument. The Schedule lists the drugs that are to be removed from the PBS, including Aluminium Hydroxide, Dried with Magnesium Hydroxide and Oxethazaine, Chloramphenicol Sodium Succinate, and Methacycline Hydrochloride. Under this Act, the Assistant Secretary and Delegate of the Minister for Health and Family Services are tasked with ensuring that the specified drugs are no longer considered eligible for the benefits outlined in Part VII of the National Health Act 1953. This involves formalising the decision through a legislative instrument, which is done in accordance with the procedural requirements set out in the National Health Act 1953. The role of the Pharmaceutical Benefits Advisory Committee is to provide advice on the suitability of these drugs for inclusion or exclusion from the PBS. In terms of obligations, the Act imposes a clear requirement on the Assistant Secretary to consult with the Pharmaceutical Benefits Advisory Committee before making any declaration under subsection 85(2AA). This ensures that the decision to remove drugs from the PBS is informed and evidence-based. Additionally, the declaration itself must be made in the specified format, with a clear statement of the drugs affected and the effective date of the changes. The legislative instrument must also be dated and signed by the appropriate authority, as evidenced by the signature of D. GRAHAM on 8 April 1998. Regarding consequences, the Act does not explicitly detail offences, penalties, or specific consequences for non-compliance with its provisions. However, the legislative process itself underscores the importance of adhering to the outlined procedures. Any failure to consult with the Pharmaceutical Benefits Advisory Committee or to properly execute the declaration could potentially undermine the integrity of the decision-making process for the PBS. While the Act does not specify maximum penalties, any breaches of the legislative process might lead to administrative or legal scrutiny, potentially resulting in the nullification of the declaration or other corrective measures deemed necessary by the appropriate authorities.